Orchestra Biomed Holdings, Inc.
Industry Group: Healthcare
Country/Region: United States of America
Identifier: NAS:OBIO
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Healthcare 525 out of 563
Universe
Global Universe 12015 out of 14634
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Sedana Medical AB |
28.5
Medium
|
355 out of 563 |
The Beauty Health Co. |
30.5
High
|
404 out of 563 |
KORU Medical Systems, Inc. |
31
High
|
423 out of 563 |
HUMASIS Co., Ltd. |
32.9
High
|
478 out of 563 |
Orchestra Biomed Holdings, Inc. |
34.9
High
|
525 out of 563 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Orchestra Biomed Holdings, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Orchestra Biomed Holdings, Inc.'s Management of ESG Material Risk is Weak